Published online Jan 26, 2019. doi: 10.12998/wjcc.v7.i2.171
Peer-review started: October 25, 2018
First decision: November 28, 2018
Revised: December 27, 2018
Accepted: January 3, 2019
Article in press: January 3, 2019
Published online: January 26, 2019
Processing time: 93 Days and 22.1 Hours
Exosomes are microvesicles, measuring 30-100 nm in diameter. They are widely distributed in body fluids, including blood, bile, urine and saliva. Cancer-derived exosomes carry a wide variety of DNA, RNA, proteins and lipids, and may serve as novel biomarkers in cancer.
To summarize the performance of exosomal biomarkers in cancer diagnosis and prognosis.
Relevant publications in the literature were identified by search of the “PubMed” database up to September 11, 2018. The quality of the included studies was assessed by QUADAS-2 and REMARK. For assessment of diagnostic biomarkers, 47 biomarkers and 2240 patients from 30 studies were included.
Our results suggested that these exosomal biomarkers had excellent diagnostic ability in various types of cancer, with good sensitivity and specificity. For assessment of prognostic markers, 50 biomarkers and 4797 patients from 42 studies were included. We observed that exosomal biomarkers had prognostic values in overall survival, disease-free survival and recurrence-free survival.
Exosomes can function as potential biomarkers in cancer diagnosis and prognosis.
Core tip: Cancer-derived exosomes carry a wide variety of DNA, RNA, proteins and lipids, which may serve as novel biomarkers in cancer. The current systematic review and meta-analysis summarized the performance of exosomal biomarkers in cancer diagnosis and prognosis. We analyzed 47 diagnostic markers and 50 prognostic markers from 56 studies with various type of cancer. We found that exosomal biomarkers had both diagnostic and prognostic power in many cancers.